Business
UPDATE - BioElectronics' President Discusses Company's Many Opportunities
UPDATE - BioElectronics' President Discusses Company's Many Opportunities.
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n \n \n UPDATE - BioElectronics' President Discusses Company's Many Opportunities\n \n \nUPDATE - BioElectronics' President Discusses Company's Many Opportunities\n \n FREDERICK, MD--(Marketwired - Aug 22, 2017) - The following is a statement from BioElectronics (OTC PINK: BIEL).\n Dear Fellow Shareholders,\n These are busy and exciting times at BioElectronics. \n New Product Opportunities\n Over the last few years, there have been two significant developments: 1) There has been a paradigm shift in the medical community's understanding of how chronic pain develops, and 2) There is evidence that BioElectronics' technology platform (Pulsed Shortwave Therapy) works by regulating the activity of nerves in the body, i.e. by neuromodulation. Together they present an excellent opportunity to position ActiPatch as the ideal therapy against chronic musculoskeletal pain.\n When pain signals from an injury repeatedly attack the nervous system, the nerves become \"sensitized\". Due to this, the nerves \"learn\" pain and continue to overreact long after the injury has healed, leading to a condition known as \"central sensitization\". Individuals who have developed central sensitization will experience hyperalgesia (excessive pain) from movements or allodynia (false pain), both of which can become chronic. The key to chronic pain relief lies in disrupting the irregular pain signals. The ActiPatch's signal allows nerves to \"learn\" this new, harmless information (ActiPatch signal) over time, thus disrupting irregular pain signals. The nerves cannot adapt to ActiPatch's pulsed signal, allowing continuous use for 24/7 pain relief. This short video http://actipatch.com/why-actipatch/ features Kenneth J. McLeod, Ph.D., Director of the Clinical Science and Engineering Research Center at Binghamton University, outlines how ActiPatch mitigates central sensitization. \n Central sensitization is responsible for many other neurological disorders: migraines, overactive bladder, primary dysmenorrhea, endometriosis, fibromyalgia etc. have all been linked to hypersensitive responses of the central nervous system. The neuromodulation basis of the BioElectronics product line supports broad product opportunities in: \n \n \n Musculoskeletal Pain\n \nMenstrual Pain\n \nHeel and Foot Pain\n \nMigraine Headaches\n \nPostoperative Recovery and Pai...